Novavax Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:3em;'>NVA</div>
NVAX -- USA Stock  

USD 122.40  2.65  2.12%

Novavax Accrued Expenses Turnover is fairly stable at the moment as compared to the past year. Novavax reported Accrued Expenses Turnover of 0.84 in 2019. Cash and Equivalents Turnover is likely to rise to 0.38 in 2020, whereas Net Income Per Employee is likely to drop (867.7 K) in 2020. If you have been following Novavax you may be considering acquiring. Let's check if strong basic indicators will continue to push the price to rise for Novavax's investors. Novavax current probability of bankruptcy is under 14 percent. Will investors continue to be optimistic, or should we expect a sell-off?
Published over a month ago
View all stories for Novavax | View All Stories
Does Novavax (NASDAQ:NVAX) have strong basic indicators based on the current rise?
On a scale of 0 to 100, Novavax holds a performance score of 4. The company secures a Beta (Market Risk) of 0.7173, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Novavax's beta means in this case. As returns on the market increase, Novavax returns are expected to increase less than the market. However, during the bear market, the loss on holding Novavax will be expected to be smaller as well. Although it is vital to follow Novavax price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Novavax technical indicators, you can presently evaluate if the expected return of 0.38% will be sustainable into the future. Please exercises Novavax jensen alpha and semi variance to make a quick decision on whether Novavax current price movements will revert.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Novavax income statement, its balance sheet, and the statement of cash flows. Potential Novavax investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Novavax investors may use each financial statement separately, they are all related. The changes in Novavax's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novavax's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Novavax fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Novavax performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Novavax shares is the value that is considered the true value of the share. If the intrinsic value Novavax is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Novavax. Please read more on our fundamental analysis page.

Are Novavax Earnings Expected to grow?

The future earnings power of Novavax involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Novavax factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Novavax stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Novavax expected earnings.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Novavax, but it might be worth checking our own buy vs. sell analysis

Novavax Gross Profit

Novavax Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Novavax previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Novavax Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Exercise or conversion by James Young of 10000 shares of Novavax subject to Rule 16b-3

Legal trades by Novavax insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Novavax insider trading alert for exercise of restricted stock units by James Young, the corporate stakeholder, on 5th of January 2021. This event was filed by Novavax Inc with SEC on 2021-01-05. Statement of changes in beneficial ownership - SEC Form 4. James Young currently serves as independent chairman of the board of Novavax [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On Novavax

Institutional investor usually refers to an organization that invests money in Novavax on behalf of clients or other money managers. Buying and selling of large positions of Novavax stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Novavax stock. Let's take a look at how the ownership of Novavax is distributed among investors.

Ownership Allocation

Novavax maintains a total of sixty-three million six hundred sixty thousand outstanding shares. Over half of Novavax outstanding shares are owned by institutional investors. These institutional investors are typically referred to corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Novavax. Please watch out for any change in the institutional holdings of Novavax as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors
Retail Investors49.02

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novavax has an asset utilization ratio of 53.04 percent. This suggests that the company is making $0.53 for each dollar of assets. An increasing asset utilization means that Novavax is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
129.2 M
Assets Non Current
83.1 M
60.2 M
Current Assets129.21 Million47.42
Assets Non Current83.1 Million30.5
Goodwill60.18 Million22.09

Will Novavax current rise continue?

The downside deviation is down to 5.82 as of today. Novavax is displaying above-average volatility over the selected time horizon. Investors should scrutinize Novavax independently to ensure intended market timing strategies are aligned with expectations about Novavax volatility.

The Current Takeaway on Novavax Investment

While many other companies under the biotechnology industry are still a bit expensive, Novavax may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Novavax valuation and our trade advice on Novavax is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Novavax.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Novavax. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to